ArticleDrug design, development and therapy2025

Efficacy and Safety of Rituximab in Treating Adult Patients with Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Prospective Study Compared with Glucocorticoids.

Yong Xin Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.